Evidence map›Paper›PMID 32907759›Full record

ReviewVaccine2020

The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines.

Richard C Condit, Denny Kim, James S Robertson, Jean-Louis Excler, Marc Gurwith, Thomas P Monath, George Pavlakis, Patricia E Fast, Jonathan Smith, Emily R Smith and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Vaccine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Richard C ConditDepartment of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL 32610, USA.
Denny KimJanssen Pharmaceuticals, Titusville, NJ, USA.
James S RobertsonIndependent Adviser, United Kingdom.
Jean-Louis ExclerInternational Vaccine Institute, Seoul, Republic of Korea.
Marc GurwithBrighton Collaboration, a Program of the Task Force for Global Health, Decatur, GA, USA.
Thomas P MonathCrozet BioPharma LLC, Devens, MA 01434, USA.
George PavlakisNational Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA.
Patricia E FastInternational AIDS Vaccine Initiative, New York, NY 10004, USA; Stanford School of Medicine, Palo Alto, CA 94305, USA.
Jonathan SmithVLP Therapeutics, Gaithersburg, MD 20878, USA.
Emily R SmithBrighton Collaboration, a Program of the Task Force for Global Health, Decatur, GA, USA.
Robert T ChenBrighton Collaboration, a Program of the Task Force for Global Health, Decatur, GA, USA.
Sonali KochharGlobal Healthcare Consulting, New Delhi, India; University of Washington, Seattle, WA 98195, USA.
Brighton Collaboration Benefit-Risk Assessment of Vaccines by Technology (BRAVATO) Working Group. Electronic address: bc-coordinator@taskforce.org

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many of the vaccines under development for COVID-19 involve the use of viral vectors. The Brighton Collaboration Benefit-Risk Assessment of Vaccines by Technology (BRAVATO, formerly the Viral Vector Vaccine Safety Working Group, V3SWG) working group has prepared a standardized template to describe the key considerations for the benefit-risk assessment of viral vector vaccines. This will facilitate key stakeholders to anticipate potential safety issues and interpret or assess safety data. This would also help improve communication and public acceptance of licensed viral vector vaccines.

Indexed as

AnimalsDrug Evaluation, PreclinicalGenetic VectorsHumansInternetRisk AssessmentVaccines, AttenuatedViral VaccinesVaccines, AttenuatedViral VaccinesBenefit-riskBrighton CollaborationCEPICOVID-19SafetyTemplateVaccineVectorViralVirus

Identifiers

PMID32907759
PMCPMC7474958

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.